ClearPoint Neuro, Inc. (NASDAQ:CLPT) Shares Bought by Barclays PLC

Barclays PLC increased its stake in ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) by 1,070.9% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 66,436 shares of the company's stock after acquiring an additional 60,762 shares during the quarter. Barclays PLC owned approximately 0.24% of ClearPoint Neuro worth $1,022,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. JPMorgan Chase & Co. boosted its stake in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock worth $110,000 after purchasing an additional 3,612 shares during the period. Conway Capital Management Inc. lifted its holdings in shares of ClearPoint Neuro by 13.9% during the 4th quarter. Conway Capital Management Inc. now owns 161,225 shares of the company's stock valued at $2,480,000 after buying an additional 19,725 shares during the last quarter. Geode Capital Management LLC grew its stake in shares of ClearPoint Neuro by 1.5% in the 3rd quarter. Geode Capital Management LLC now owns 287,294 shares of the company's stock valued at $3,222,000 after buying an additional 4,170 shares in the last quarter. Invesco Ltd. acquired a new position in ClearPoint Neuro in the fourth quarter worth approximately $3,814,000. Finally, Bradley Foster & Sargent Inc. CT bought a new position in ClearPoint Neuro during the fourth quarter valued at approximately $871,000. 30.08% of the stock is currently owned by institutional investors and hedge funds.

ClearPoint Neuro Price Performance

NASDAQ CLPT opened at $13.88 on Tuesday. The company's fifty day moving average is $12.86 and its two-hundred day moving average is $14.20. The firm has a market capitalization of $388.36 million, a price-to-earnings ratio of -20.12 and a beta of 1.03. ClearPoint Neuro, Inc. has a 52-week low of $5.11 and a 52-week high of $19.22.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last issued its earnings results on Wednesday, February 26th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.05). ClearPoint Neuro had a negative return on equity of 62.10% and a negative net margin of 59.64%. The firm had revenue of $7.77 million during the quarter, compared to the consensus estimate of $8.23 million. As a group, sell-side analysts expect that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. B. Riley lifted their price objective on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. Lake Street Capital upped their price objective on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the stock a "buy" rating in a report on Tuesday, January 21st. Finally, Stifel Nicolaus lifted their price objective on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st.

ClearPoint Neuro Profile

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.